Cleared Special

ACCESS OV MONITOR ASSAY (K031297) - FDA 510(k) Clearance

Class II Immunology device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K031297 · Beckman Coulter, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2003
Decision
8d
Days
Class 2
Risk

K031297 is an FDA 510(k) clearance for the ACCESS OV MONITOR ASSAY. Classified as Test, Epithelial Ovarian Tumor-associated Antigen (ca125) (product code LTK), Class II - Special Controls.

Submitted by Beckman Coulter, Inc. (Chaska, US). The FDA issued a Cleared decision on May 2, 2003 after a review of 8 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.6010 - the FDA immunology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Beckman Coulter, Inc. devices

Submission Details

510(k) Number K031297 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 24, 2003
Decision Date May 02, 2003
Days to Decision 8 days
Submission Type Special
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
96d faster than avg
Panel avg: 104d · This submission: 8d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code LTK Test, Epithelial Ovarian Tumor-associated Antigen (ca125)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.6010
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LTK Test, Epithelial Ovarian Tumor-associated Antigen (ca125)

All 25
Devices cleared under the same product code (LTK) and FDA review panel - the closest regulatory comparables to K031297.
Access OV Monitor
K240479 · Beckman Coulter, Inc. · May 2024
IMMULITE/IMMULITE 1000 OM-MA, IMMULITE 2000 OM-MA
K213510 · Siemens Healthcare Diagnostics Products, Ltd. · Sep 2023
VITROS Immuodiagnostic Products CA 125 II Reagent Pack
K221355 · Ortho-Clinical Diagnostics · Dec 2022
ADVIA Centaur CA 125II
K200199 · Siemens Healthcare Diagnostics, Inc. · Apr 2020
VIDAS CA 15-3 ASSAY
K080469 · bioMerieux, Inc. · Jun 2009
VIDAS CA 125 II ASSAY
K080561 · bioMerieux, Inc. · Apr 2009